Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 4/20 | 0.40 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22470606 | 0.98 | XDH (0.47) | XDHMAOAMAOBCHRM4PDE5A | |
| SCHEMBL23099080 | 0.92 | CHRM4 (0.43) | XDHCHRM4GPR6EPAS1AR | |
| SCHEMBL22470817 | 0.85 | TBK1 (0.51) | IKBKETBK1 | |
| SCHEMBL3083289 | 0.85 | HTR1A (0.48) | IKBKETBK1 | |
| SCHEMBL29847200 | 0.85 | TBK1 (0.51) | IKBKETBK1 | |
| SCHEMBL15819822 | 0.82 | CHRM4 (0.43) | CHRM4EPAS1AR | |
| SCHEMBL17306341 | 0.81 | XDH (0.46) | XDHMAOAMAOBPDE5APDE1A | |
| SCHEMBL29846992 | 0.81 | TBK1 (0.40) | CHRM4GPR6EPAS1ARIKBKE | |
| SCHEMBL6052399 | 0.81 | KDM4E (0.54) | XDHMAOAMAOBPDE5APDE1A | |
| SCHEMBL23753850 | 0.81 | TBK1 (0.40) | CHRM4GPR6EPAS1ARIKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | XDH 1547/4885MAOA 807/4885MAOB 463/4885 |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | XDH 1547/4885MAOA 807/4885MAOB 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.